Results 111 to 120 of about 121,509 (248)

Armored Chimeric Antigen Receptor T-cell Therapy Targets Antigen-Heterogeneous Glioma. [PDF]

Cancer Res
Clubb JD, Shih RM, Gao TA, Shafer A, Vajragiri S, Lam K, Talluri S, Bouren A, Brown CE, Ruivo P, Prins RM, Wu HC, Chen YY.   +12 more
europepmc   +1 more source

Tackling cancer stemness with nanotechnology in the era of precision medicine

BMEMat, EarlyView.
Precise customization of nanoparticles (NPs) enables active targeting of cancer stem cells (CSCs), thereby improving drug delivery and therapeutic efficacy. NP‐based probing enhances CSC detection through imaging and liquid biopsy, whereas diverse therapeutic payloads improve therapeutic outcomes.
Shaolei Guo, Shun Yao, Lihui Meng, Chunyuan Chen, Yuechu Lucinda Lu, Rong Lu, Kashif Rafiq Zahid, Umar Raza, Qingzhi Wu, Wenli Chen   +9 more
wiley   +1 more source

Chimeric antigen receptor technology: an emerging translational immunotherapy in nonneoplastic diseases. [PDF]

Front Immunol
Zhou S, Li Y, Zhao J, Zhan W, Zhou C, Zou Y, Li X, Cui J, Wu J, Xia J.   +9 more
europepmc   +1 more source

Status and future of recombinant adeno‐associated virus vector manufacturing

Biotechnology Progress, EarlyView.
Abstract Sixty years of adeno‐associated virus (AAV) research illustrates a trajectory marked by basic science exploration, iterative innovation, persistent challenges, a number of clinical setbacks, as well as commercial therapeutic triumphs. This continual evolution has led to recombinant AAV (rAAV) becoming a cornerstone of modern gene therapy ...
Frank Agbogbo, David Dismuke
wiley   +1 more source

Neurological implications of chimeric antigen receptor-T cell therapy. [PDF]

BMJ Neurol Open
Raffoul DG, Roos I, Mulazzani M, Anderson MA, Monif M, Garber J, van der Walt A, Massey J, Kuznetsova V, Nesbitt C, Dowling M, Ruderman I, Lasocki A, Tam CS, Harrison SJ, Kalincik T.   +15 more
europepmc   +1 more source

From Caffeine to Aspirin: Everyday Molecules as Triggers for Genetically Encoded Proximity Systems

Chemistry – A European Journal, EarlyView.
This Perspective article highlights how familiar dietary ingredients and over‐the‐counter (OTC) drugs (such as caffeine and its metabolites, SA, and aspirin) can be repurposed as clinically translatable chemical triggers for genetically encoded proximity systems.
Mingguang Cui, Tianlu Wang, Yaoyu Han, Yun Huang, Tien‐Hung Lan, Yunbin Zhou   +5 more
wiley   +1 more source

Development and characterization of chimeric antigen receptor macrophages for amyloid clearance. [PDF]

Front Immunol
Balachandran M, Foster JS, Hancock TJ, Martin EB, Jackson JW, Angell N, Wall JS.   +6 more
europepmc   +1 more source

Model‐Based Analysis with Mechanistic Insights to CAR‐T‐Cell Therapy Kinetics: Case Study with Axicabtagene Ciloleucel and Brexucabtagene Autoleucel

Clinical Pharmacology &Therapeutics, EarlyView.
Model‐informed drug development is increasingly used to support chimeric antigen receptor (CAR)‐T‐cell therapy programs. However, most population pharmacokinetic (PK) CAR‐T‐cell models available in literature are variations of an empirical piecewise‐linear model, which accurately describes the observed data but lacks a mechanistic foundation.
Anna M. Mc Laughlin, Martin Bergstrand, Ana Ruiz‐Garcia, Simone Filosto, Rhine Shen   +4 more
wiley   +1 more source

The Multiple Criteria Qualitative Value‐Based Pricing Framework “MARIE” for Novel Cell and Gene Therapy

Clinical Pharmacology &Therapeutics, EarlyView.
When setting the price of cell and gene therapies in Japan, the factors considered include the manufacturing and operating costs of the new drug or a comparator, leading to discrepancies between price and values, in particular those specific to cell and gene therapies.
Akina Takami, Ataru Igarashi
wiley   +1 more source

Engineering chimeric antigen receptor CD4 T cells for Alzheimer's disease. [PDF]

Proc Natl Acad Sci U S A
Boskovic P, Shalita R, Gao W, Vernon H, Deng YL, Colonna M, Majzner RG, Amit I, Kipnis J.   +8 more
europepmc   +1 more source